Drug-induced immune hemolytic anemia associated with albumin-bound paclitaxel

Article Type

Changed

Thu, 12/15/2022 - 18:03

Display Headline

Author(s)

Drug-induced immune hemolytic anemia is rare, with only 1 patient in 1 million affected by the condition. Garratty identified 125 drugs indicated in DIIHA of which 11% were antineoplastic agents, and neither paclitaxel nor albumin-bound paclitaxel were included. In addition, we did not find any reports in our own search of the literature. Taxanes are known to cause anemia as a result of their myelosuppressive effects, but an immune hemolysis is rare. To our knowledge, we present here the first case of DIIHA with nab-paclitaxel.

Click on the PDF icon at the top of this introduction to read the full article.

Article PDF

JCSO_aug_298_Thomas.pdf

Issue

The Journal of Community and Supportive Oncology - 13(8)

Publications

The Journal of Community and Supportive Oncology

MDedge Hematology and Oncology

Breast Cancer ICYMI

Topics

Breast Cancer

Patient & Survivor Care

Page Number

298-299

Legacy Keywords

drug-induced immune hemolytic anemia, DIIHA, antineoplastic agents, paclitaxel, albumin-bound paclitaxel, nab-paclitaxel, immune hemolysis

Sections

Case Reports

Author(s)

Roby Thomas et al

Author(s)

Roby Thomas et al

Article PDF

JCSO_aug_298_Thomas.pdf

Article PDF

JCSO_aug_298_Thomas.pdf

Drug-induced immune hemolytic anemia is rare, with only 1 patient in 1 million affected by the condition. Garratty identified 125 drugs indicated in DIIHA of which 11% were antineoplastic agents, and neither paclitaxel nor albumin-bound paclitaxel were included. In addition, we did not find any reports in our own search of the literature. Taxanes are known to cause anemia as a result of their myelosuppressive effects, but an immune hemolysis is rare. To our knowledge, we present here the first case of DIIHA with nab-paclitaxel.

Click on the PDF icon at the top of this introduction to read the full article.

Drug-induced immune hemolytic anemia is rare, with only 1 patient in 1 million affected by the condition. Garratty identified 125 drugs indicated in DIIHA of which 11% were antineoplastic agents, and neither paclitaxel nor albumin-bound paclitaxel were included. In addition, we did not find any reports in our own search of the literature. Taxanes are known to cause anemia as a result of their myelosuppressive effects, but an immune hemolysis is rare. To our knowledge, we present here the first case of DIIHA with nab-paclitaxel.

Click on the PDF icon at the top of this introduction to read the full article.

Issue

The Journal of Community and Supportive Oncology - 13(8)

Issue

The Journal of Community and Supportive Oncology - 13(8)

Page Number

298-299

Page Number

298-299

Publications

The Journal of Community and Supportive Oncology

MDedge Hematology and Oncology